Clinical outcomes among hospital patients with Middle East respiratory syndrome coronavirus (MERS-CoV) infection
ribavirin, interferon alpha, MERS-CoV, Mortality
Abstract Background Mortality is high among patients with Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection. We aimed to determine hospital mortality and the factors associated with it in a cohort of MERS-CoV patients. Methods We reviewed hospital records of confirmed cases (detection of virus by polymerase chain reaction from respiratory tract samples) of MERS-CoV patients (n = 63) admitted to Buraidah Central Hospital in Al-Qassim, Saudi Arabia between 2014 and 2017. We abstracted data on demography, vital signs, associated conditions presented on admission, pre-existing chronic diseases, treatment, and vital status. Bi-variate comparisons and multiple logistic regressions were the choice of data analyses. Results The mean age was 60 years (SD = 18.2); most patients were male (74.6%) and Saudi citizens (81%). All but two patients were treated with Ribavirin plus Interferon. Hospital mortality was 25.4%. Patients who were admitted with septic shock and/or organ failure were significantly more likely to die than patients who were admitted with pneumonia and/or acute respiratory distress syndrome (OR = 47.9, 95% CI = 3.9, 585.5, p-value 0.002). Age, sex, and presence of chronic conditions were not significantly associated with mortality. Conclusion Hospital mortality was 25%; septic shock/organ failure at admittance was a significant predictor of mortality.
Abdulrahman Mohammed G. Habib, Mohamed Abd Elghafour Ali, Baha R. Zouaoui, Mustafa Ahmed H. Taha, Bassem Sahsah Mohammed, Nazmus Saquib